Enhanced bacterial tumor delivery by modulating the EPR effect and therapeutic potential of lactobacillus casei

Journal of Pharmaceutical Sciences

Volumn 103, Issue 10, 2014, Pages 3235-3243

  Fang, Jun ^a   Liao, Long ^a   Yin, Hongzhuan ^a,b   Nakamura, Hideaki ^a   Shin, Takashi ^a   Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Ace inhibitor; Cancer; Distribution; Epr effect; Lactobacillus casei; Nanotechnology; Nitroglycerin; Permeability; Targeted drug delivery; Vascular permeability

Indexed keywords

ENALAPRIL; GLYCERYL TRINITRATE; LACTOBACILLUS CASEI EXTRACT; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GROWTH; CANCER GROWTH; COLON ADENOCARCINOMA; CONTROLLED STUDY; ELECTRIC POTENTIAL; ENHANCED PERMEABILITY AND RETENTION EFFECT; ENZYME ACTIVITY; FEMALE; IMMUNE RESPONSE; LACTOBACILLUS CASEI; LIVER; MALE; MOUSE; NONHUMAN; PERMEABILITY; SPLEEN; TUMOR MICROENVIRONMENT; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; ELECTRON SPIN RESONANCE; NEOPLASMS;

ANIMALS; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENALAPRIL; FEMALE; LACTOBACILLUS CASEI; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS; NITRIC OXIDE SYNTHASE; NITROGLYCERIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923364283     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24083     Document Type: Article

References (40)

1. Coley WB. 1910. The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus). Proc R Soc Med 3:1-48.
2. Decker WK, Safdar A. 2009. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev 20:271-281.
3. Hoffman RM. 2009. Tumor-targeting amino acid auxotrophic Salmonella typhimurium. Amino Acids 37:509-521.
4. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, Hoffman RM. 2005. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. ProcNatl Acad Sci USA 102:755-760.
5. Sasaki T, Fujimori M, Hamaji Y, Hama Y, Ito K, Amano J, Taniguchi S. 2006. Genetically engineered Bifidobacterium longum for tumortargeting enzyme-prodrug therapy of autochthonousmammary tumors in rats. Cancer Sci 97:649-657.
6. Xiang S, Fruehauf J, Li CJ. 2006. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 24:697-702.
7. Nanno M, Kato I, Kobayashi T, Shida K. 2011. Biological effects of probiotics: What impact does Lactobacillus casei shirota have on us? Int J Immunopathol Pharmacol 24:45S-50S.
8. Matsuzaki T. 1998. Immunomodulation by treatment with Lactobacillus casei strain Shirota. Int J Food Microbiol 41:133-140.
9. Malmgren RA, Flanigan CC. 1955. Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res 15:473-478.
10. M öse JR, M öse G. 1964. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 24:212-216.
11. Kimura NT, Taniguchi S, Aoki K, Baba T. 1980. Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res 40:2061-2068.
12. Fang J, Nakamura H, Maeda H. 2011. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136-151.
13. Matsumura Y, Maeda H. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387-6392.
14. Maeda H. 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumorselective macromolecular drug targeting. Adv Enzyme Regul 41:189-207.
15. Maeda H, Sawa T, Konno T. 2001. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47-61.
16. MaedaH. 2001. SMANCS and polymer-conjugated macromolecular drugsAdvantages in cancer chemotherapy. Adv DrugDeliv Rev 46:169-185.
17. Seki T, Fang J, Maeda H. 2009. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci 100:2426-2430.
18. Maeda H. 2012. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 88:53-71.
19. Burke AJ, Sullivan FJ, Giles FJ, Glynn SA. The yin and yang of nitric oxide in cancer progression. Carcinogenesis 2013;34:503-512.
20. Kato I, Kobayashi S, Yokokura T, Mutai M. 1981. Antitumor activity of Lactobacillus casei in mice. Gann 72:517-523.
21. Kato I, Yokokura T, Mutai M. 1985. Induction of tumoricidal peritoneal exudate cells by administration of Lactobacillus casei. Int J Immunopharmacol 7:103-109.
22. Kato I, Yokokura T, Mutai M. 1983. Macrophage activation by Lactobacillus casei in mice. Microbiol Immunol 27:611-618.
23. Kato I, Yokokura T, Mutai M. 1984. Augmentation of mouse natural killer cell activity by Lactobacillus casei and its surface antigens. Microbiol Immunol 28:209-217.
24. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. 1995. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol 27:104-109.
25. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N, Kitamura T, Kawabe K, Kotake T, Kuroda M, Naito S, Koga H, Saito Y, Nomata K, Kitagawa M, Aso Y. 2002. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int 68:273-280.
26. Sylvester RJ, van der Meijden AP, Lamm DL. 2002. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 168:1964-1970.
27. Feelisch M, Noack EA. 1987. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 139:19-30.
28. Chen Z, Stamler JS. 2006. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med 16:259-265.
29. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. 2000. Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: Monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 48:565-570.
30. Noguchi A, Takahashi T, Yamaguchi T, Kitamura K, Noguchi A, TsurumiH, Takashina K, MaedaH. 1992. Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn J Cancer Res 83:240-243.
31. Maruyama K. 2011. Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. AdvDrugDeliv Rev 63:161-169.
32. Cabral H, Matsumoto Y, Mizuno K, Chen Q, Murakami M, Kimura M, Terada Y, Kano MR, Miyazono K, Uesaka M, Nishiyama N, Kataoka K. 2011. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 6:815-823.
33. Kano MR, Bae Y, Iwata C, Morishita Y, Yashiro M, Oka M, Fujii T, Komuro A, Kiyono K, Kaminishi M, Hirakawa K, Ouchi Y, Nishiyama N, Kataoka K, Miyazono K. 2007. Improvement of cancertargeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signaling. Proc Natl Acad Sci USA 104:3460-3465.
34. Buckway B, Wang Y, Ray A, Ghandehari H. 2013. Overcoming the stromal barrier for targeted delivery of HPMA copolymers to pancreatic tumors. Int J Pharm 456:202-211.
35. Yasuda H, Nakayama K,Watanabe M, Suzuki S, Fuji H, Okinaga S, Kanda A, Zayasu K, Sasaki T, Asada M, Suzuki T, YoshidaM, Yamanda S, Inoue D, Kaneta T, Kondo T, Takai Y, Sasaki H, Yanagihara K, Yamaya M. 2006. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 12:6748-6757.
36. Mitchell JB, Wink DA, DeGraff W, Gamson J, Keefer LK, Krishna MC. 1993. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 53:5845-5848.
37. Castillo NA, Perdig ón G, de Moreno de Leblanc A. 2011. Oral administration of a probiotic Lactobacillus modulates cytokine production and TLR expression improving the immune response against Salmonella enterica serovar Typhimurium infection in mice. BMC Microbiol 11:177.
38. Maeda H,Matsumura Y, Molla A. 1987. Antitumor activity of some bacterial proteases: Eradication of solid tumors in mice by intratumor injection. Cancer Res 47:563-566.
39. Maeda H, Molla A, Sakamoto K, Murakami A, Matsumura Y. 1989. Cytotoxicity of bacterial proteases in various tumor cells mediated through alpha 2-macroglobulin receptor. Cancer Res 49:660-664.
40. Murakami A, Sakamoto K, Kojima Y, Sasaki Y, Maeda H. 1992. Antitumor effect of bacterial proteases on various human cancer xenografts in nude mice. Reg Cancer 4:200-206.